Delisting risk
Cardio Diagnostics
Develops genetic-epigenetic blood tests and clinical intelligence for coronary heart disease.
$1.85
After-hours close+0.03 (+1.65%)
At close$1.82(−2.91%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | — | — | — |
| Aug 2026 | — | −$0.51 | — |
| May 2026 | — | −$0.63 | — |
| Mar 2026 | −$1.80 | −$0.80 | +55.6% |
| Nov 2025 | −$1.80 | −$0.98 | +45.6% |
The latest year is open to everyone — the 19 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Dec 2021 | |||
| Jun 2021 | |||
| Mar 2021 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Nov 6, 2026 | — | — | — | — | — | — |
| Aug 7, 2026 | — | −$0.51 | — | — | $5.4K | — |
| May 15, 2026 | — | −$0.63 | — | — | $2.7K | — |
| Mar 13, 2026 | −$1.80 | −$0.80 | +55.6% | $250.0K | $3.6K | −98.6% |
| Nov 12, 2025 | −$1.80 | −$0.98 | +45.6% | $150.0K | $2.9K | −98.1% |
The latest year is open to everyone — the 19 quarters behind it read with an account. Sign in | ||||||
| Aug 14, 2025 | ||||||
| May 15, 2025 | ||||||
| Mar 20, 2025 | ||||||
| Nov 13, 2024 | ||||||
| Aug 12, 2024 | ||||||
| May 15, 2024 | ||||||
| Mar 25, 2024 | ||||||
| Feb 12, 2024 | ||||||
| Nov 13, 2023 | ||||||
| Aug 14, 2023 | ||||||
| May 26, 2023 | ||||||
| Mar 31, 2023 | ||||||
| Nov 7, 2022 | ||||||
| Aug 10, 2022 | ||||||
| May 12, 2022 | ||||||
| Mar 31, 2022 | ||||||
| Dec 31, 2021 | ||||||
| Jun 30, 2021 | ||||||
| Mar 31, 2021 | ||||||